AERI Aerie Pharmaceuticals, Inc.

+1  (2%)
Previous Close 47.45
Open 47.40
Price To book 15.07
Market Cap 1.62B
Shares 33,626,000
Volume 268,562
Short Ratio 10.28
Av. Daily Volume 393,092

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
Roclatan - Mercury trials
NDA Filing September 6, 2016 withdrawn due to third party manufacturing issues. NDA resubmission announced March 1, 2017.

Latest News

  2. Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction
  3. AERIE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  4. Aerie Pharma downgraded by Raymond James
  5. Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted
  6. Aerie reports 4Q loss
  7. Aerie reports 4Q loss
  8. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  9. Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  10. Q4 2016 Aerie Pharmaceuticals Inc Earnings Release - After Market Close
  11. 4 Small-Cap Biotech Stars
  12. Aerie Pharmaceuticals to Present at Three Investor Conferences in March
  13. Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
  14. AERIE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  15. Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%
  16. Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017
  17. Aerie Pharmaceuticals to Present at the RBC Capital Markets 2017 Global Healthcare Conference
  18. Post Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates
  19. Aerie Pharmaceuticals Announces Appointment of Huan Sheng, M.D., Ph.D., as Director Clinical Research and Drug Safety
  20. Aerie Pharmaceuticals Announces Appointment of Barry Ivin as Site Director of New Manufacturing Plant in Ireland